European Centre for Disease Prevention and Control, Stockholm, Sweden.
Centre for Infectious Disease Control (Cib), National Institute for Public Health and the Environment (RIVM), Bilthoven, The Netherlands.
Euro Surveill. 2024 Nov;29(47). doi: 10.2807/1560-7917.ES.2024.29.47.2400587.
BackgroundNew Delhi metallo-beta-lactamase (NDM)-producing has been reported from European Union/European Economic Area (EU/EEA) countries with increasing frequency. During 2018 to 2022, 355 cases of NDM-producing were detected in seven hospitals reporting on NDM-production in Enterobacterales in Romania.AimOur aim was to determine the extent of spread of NDM-producing in hospitals in Romania.MethodsWe analysed whole genome sequences and epidemiological data of 74 isolates collected in six hospitals from December 2021 to September 2023.ResultsWe identified four multi-hospital clusters including isolates detected over more than a year, indicating sustained spread of -carrying within the healthcare system. These clusters consisted of isolates from up to four hospitals and three regions. Three multi-hospital clusters were caused by a specific multidrug-resistant sequence type 46 lineage carrying and a large set of additional resistance markers. Investigation in an international context showed that this lineage had already been detected in nine countries (Bulgaria, France, Germany, Ireland, the Netherlands, Romania, Switzerland, United Kingdom, United States) since 2015.ConclusionOur results alert about the risk of carbapenem-resistant transmission in healthcare settings. Enhanced infection prevention and control measures should be instituted as soon as cases are detected in healthcare facilities. National surveillance systems in EU/EEA countries should, in addition to carbapenem-resistant and/or carbapenemase-producing and , consider reporting carbapenem-resistant and/or carbapenemase-producing and other Enterobacterales where relevant.
新德里金属β-内酰胺酶(NDM)产生的 已在欧盟/欧洲经济区(EU/EEA)国家中越来越频繁地报道。2018 年至 2022 年,罗马尼亚 7 家报告肠杆菌科中产 NDM 的医院共检测到 355 例 NDM 产生 。
确定 NDM 产生的 在罗马尼亚医院中的传播程度。
我们分析了 2021 年 12 月至 2023 年 9 月在六家医院收集的 74 株分离株的全基因组序列和流行病学数据。
我们确定了四个多医院集群,包括在一年以上时间内检测到的分离株,表明 - 携带菌在医疗保健系统内持续传播。这些集群由来自四个以上医院和三个地区的分离株组成。三个多医院集群是由特定的多药耐药 46 谱系引起的,该谱系携带 和一大组其他耐药标记。在国际范围内的调查显示,自 2015 年以来,该谱系已在九个国家(保加利亚、法国、德国、爱尔兰、荷兰、罗马尼亚、瑞士、英国、美国)中检测到。
我们的研究结果提醒了在医疗保健环境中传播碳青霉烯类耐药 的风险。一旦在医疗机构中发现病例,应立即采取强化感染预防和控制措施。欧盟/EEA 国家的国家监测系统除了应报告碳青霉烯类耐药和/或产碳青霉烯酶的 和 外,还应考虑报告相关的碳青霉烯类耐药和/或产碳青霉烯酶的 和其他肠杆菌科。